Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments ...

Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...

Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy ...

Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival ...

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...